Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men

Anja Blumeyer, Antonella Tosti, Andrew Messenger, Pascal Reygagne, Veronique Del Marmol, Phyllis I. Spuls, Myrto Trakatelli, Andreas Finner, Franklin Kiesewetter, Ralph Trüeb, Berthold Rzany, Ulrike Blume-Peytavi

Research output: Contribution to journalArticle

122 Citations (Scopus)

Abstract

Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. copy; 2011 Blackwell Verlag GmbH, Berlin.

Original languageEnglish
JournalJDDG - Journal of the German Society of Dermatology
Volume9
Issue numberSUPPL. 6
DOIs
StatePublished - Oct 1 2011

Fingerprint

Alopecia
Guidelines
Therapeutics
Berlin
Dermatology
General Practitioners
Quality of Life
Research

Keywords

  • alopecia
  • androgenetic
  • Guideline
  • hair loss
  • Therapy

ASJC Scopus subject areas

  • Dermatology

Cite this

Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. / Blumeyer, Anja; Tosti, Antonella; Messenger, Andrew; Reygagne, Pascal; Del Marmol, Veronique; Spuls, Phyllis I.; Trakatelli, Myrto; Finner, Andreas; Kiesewetter, Franklin; Trüeb, Ralph; Rzany, Berthold; Blume-Peytavi, Ulrike.

In: JDDG - Journal of the German Society of Dermatology, Vol. 9, No. SUPPL. 6, 01.10.2011.

Research output: Contribution to journalArticle

Blumeyer, A, Tosti, A, Messenger, A, Reygagne, P, Del Marmol, V, Spuls, PI, Trakatelli, M, Finner, A, Kiesewetter, F, Trüeb, R, Rzany, B & Blume-Peytavi, U 2011, 'Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men', JDDG - Journal of the German Society of Dermatology, vol. 9, no. SUPPL. 6. https://doi.org/10.1111/j.1610-0379.2011.07802.x
Blumeyer, Anja ; Tosti, Antonella ; Messenger, Andrew ; Reygagne, Pascal ; Del Marmol, Veronique ; Spuls, Phyllis I. ; Trakatelli, Myrto ; Finner, Andreas ; Kiesewetter, Franklin ; Trüeb, Ralph ; Rzany, Berthold ; Blume-Peytavi, Ulrike. / Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. In: JDDG - Journal of the German Society of Dermatology. 2011 ; Vol. 9, No. SUPPL. 6.
@article{e2f7b801ff504a59a5126ac5c3b10597,
title = "Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men",
abstract = "Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 {\%} Caucasian men and 42 {\%} of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. copy; 2011 Blackwell Verlag GmbH, Berlin.",
keywords = "alopecia, androgenetic, Guideline, hair loss, Therapy",
author = "Anja Blumeyer and Antonella Tosti and Andrew Messenger and Pascal Reygagne and {Del Marmol}, Veronique and Spuls, {Phyllis I.} and Myrto Trakatelli and Andreas Finner and Franklin Kiesewetter and Ralph Tr{\"u}eb and Berthold Rzany and Ulrike Blume-Peytavi",
year = "2011",
month = "10",
day = "1",
doi = "10.1111/j.1610-0379.2011.07802.x",
language = "English",
volume = "9",
journal = "JDDG - Journal of the German Society of Dermatology",
issn = "1610-0379",
publisher = "Wiley-Blackwell",
number = "SUPPL. 6",

}

TY - JOUR

T1 - Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men

AU - Blumeyer, Anja

AU - Tosti, Antonella

AU - Messenger, Andrew

AU - Reygagne, Pascal

AU - Del Marmol, Veronique

AU - Spuls, Phyllis I.

AU - Trakatelli, Myrto

AU - Finner, Andreas

AU - Kiesewetter, Franklin

AU - Trüeb, Ralph

AU - Rzany, Berthold

AU - Blume-Peytavi, Ulrike

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. copy; 2011 Blackwell Verlag GmbH, Berlin.

AB - Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80 % Caucasian men and 42 % of women. Patients diagnosed with androgenetic alopecia may undergo significant impairment of quality of life. Despite the high prevalence and the variety of therapeutic options available, there have been no national or international evidence-based guidelines for the treatment of androgenetic alopecia in men and women so far. Therefore, the European Dermatology Forum (EDF) initiated a project to develop an evidence-based S3 guideline for the treatment of andro-genetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference. The purpose of the guideline is to provide dermatologists as well as general practitioners with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia. copy; 2011 Blackwell Verlag GmbH, Berlin.

KW - alopecia

KW - androgenetic

KW - Guideline

KW - hair loss

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=80053986319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053986319&partnerID=8YFLogxK

U2 - 10.1111/j.1610-0379.2011.07802.x

DO - 10.1111/j.1610-0379.2011.07802.x

M3 - Article

C2 - 21980982

AN - SCOPUS:80053986319

VL - 9

JO - JDDG - Journal of the German Society of Dermatology

JF - JDDG - Journal of the German Society of Dermatology

SN - 1610-0379

IS - SUPPL. 6

ER -